ID24275A - Terapi kombinasi - Google Patents

Terapi kombinasi

Info

Publication number
ID24275A
ID24275A IDW20000199A ID20000199A ID24275A ID 24275 A ID24275 A ID 24275A ID W20000199 A IDW20000199 A ID W20000199A ID 20000199 A ID20000199 A ID 20000199A ID 24275 A ID24275 A ID 24275A
Authority
ID
Indonesia
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
IDW20000199A
Other languages
English (en)
Inventor
Jan Buch
Robert Andrew Donald Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID24275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID24275A publication Critical patent/ID24275A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
IDW20000199A 1997-08-29 1998-08-10 Terapi kombinasi ID24275A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
ID24275A true ID24275A (id) 2000-07-13

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000199A ID24275A (id) 1997-08-29 1998-08-10 Terapi kombinasi

Country Status (37)

Country Link
US (1) US20020025981A1 (id)
EP (1) EP1003507A1 (id)
JP (1) JP2001514224A (id)
KR (1) KR20010022385A (id)
CN (1) CN1117566C (id)
AP (1) AP1207A (id)
AR (1) AR017514A1 (id)
AU (1) AU744982B2 (id)
BG (1) BG104076A (id)
BR (1) BR9811558A (id)
CA (1) CA2296726C (id)
CO (1) CO4970726A1 (id)
DZ (1) DZ2600A1 (id)
EA (1) EA002705B1 (id)
GT (1) GT199800134A (id)
HK (1) HK1029530A1 (id)
HN (1) HN1998000124A (id)
HR (1) HRP980475A2 (id)
HU (1) HUP0003103A3 (id)
ID (1) ID24275A (id)
IL (2) IL133957A0 (id)
IS (1) IS5345A (id)
MA (1) MA26539A1 (id)
NO (1) NO20000999L (id)
NZ (1) NZ502283A (id)
OA (1) OA11289A (id)
PA (1) PA8457201A1 (id)
PE (1) PE106999A1 (id)
PL (1) PL339088A1 (id)
SA (1) SA98190432A (id)
SK (1) SK1392000A3 (id)
TN (1) TNSN98158A1 (id)
TR (1) TR200000562T2 (id)
UY (1) UY25159A1 (id)
WO (1) WO1999011263A1 (id)
YU (1) YU2700A (id)
ZA (1) ZA987843B (id)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CN101415425B (zh) * 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR101181172B1 (ko) * 2008-02-22 2012-09-18 한올바이오파마주식회사 방출성이 제어된 시간차 투여 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
KR20100008356A (ko) * 2008-07-15 2010-01-25 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
JP7306791B2 (ja) * 2015-02-06 2023-07-11 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法のための医薬組成物
WO2019094581A1 (en) * 2017-11-10 2019-05-16 Op-T Llc Methods for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2021108343A1 (en) * 2019-11-25 2021-06-03 Fordoz Pharma C0Rp. Formulations comprising lipid-lowering and blood pressure-lowering drugs
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (id) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
SA98190432A (ar) 2005-12-03
AR017514A1 (es) 2001-09-12
EP1003507A1 (en) 2000-05-31
IL133957A (en) 2006-06-11
HK1029530A1 (en) 2001-04-06
NZ502283A (en) 2002-05-31
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
KR20010022385A (ko) 2001-03-15
HUP0003103A2 (hu) 2001-01-29
US20020025981A1 (en) 2002-02-28
EA002705B1 (ru) 2002-08-29
HRP980475A2 (en) 1999-06-30
ZA987843B (en) 2000-02-28
JP2001514224A (ja) 2001-09-11
NO20000999D0 (no) 2000-02-28
CA2296726A1 (en) 1999-03-11
AP1207A (en) 2003-09-20
CN1268054A (zh) 2000-09-27
AU8458598A (en) 1999-03-22
EA200000013A1 (ru) 2000-08-28
UY25159A1 (es) 2000-12-29
AU744982B2 (en) 2002-03-07
NO20000999L (no) 2000-02-28
CN1117566C (zh) 2003-08-13
PA8457201A1 (es) 2000-05-24
AP9801333A0 (en) 1998-09-30
WO1999011263A1 (en) 1999-03-11
DZ2600A1 (fr) 2003-03-01
GT199800134A (es) 2000-02-08
PL339088A1 (en) 2000-12-04
MA26539A1 (fr) 2004-12-20
BR9811558A (pt) 2000-08-22
IL133957A0 (en) 2001-04-30
YU2700A (sh) 2002-06-19
IS5345A (is) 2000-01-14
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
CA2296726C (en) 2004-06-29
HUP0003103A3 (en) 2002-03-28
TR200000562T2 (tr) 2000-08-21
BG104076A (en) 2000-09-29
CO4970726A1 (es) 2000-11-07
HN1998000124A (es) 1999-02-09

Similar Documents

Publication Publication Date Title
ID24118A (id) Terapi gabungan
IS5425A (is) Læknislyf
ID27841A (id) Turunan-turunan biaril terapeutik
NO992806D0 (no) Terapeutiske midler
ATA93198A (de) Fluoxetinpellets
ID24275A (id) Terapi kombinasi
DE69820860D1 (de) Herzschrittmacher
DE69825349D1 (de) Motoransteuerbaugruppe
DE69836690D1 (de) Herzschrittmacher
ATA111897A (de) Kimme
NO995492L (no) Algicider
ATE236897T1 (de) 3-benzylpiperidine
DE29712035U1 (de) Therapievorrichtung
DE29703038U1 (de) Sauna
DE29710613U1 (de) Massagegerät
DE29709714U1 (de) Wasch-Geschirrspülkombination
DE29704427U1 (de) Filter-Ventilator-Einheit
ATA86797A (de) Verschleissschuh
DE29710812U1 (de) Massagegerät
ATA46498A (de) Kunststoffgleitbahn
BR9701194A (pt) Hidrociclo
DE29709146U1 (de) Massagegerät
SE9702595D0 (sv) new therapeutic use
ID19095A (id) Senyawa terapeutik fenetanolamina
SE9702610D0 (sv) Klamma